{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:45Z","timestamp":1790180925783,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502600-5"],"award-info":[{"award-number":["2022YFC2502600-5"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170163"],"award-info":[{"award-number":["82170163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01624-8","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:03:17Z","timestamp":1730109797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL\/LBL: a single-arm, phase 2 trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Jieping","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"2","key":"1624_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, et al. Early t-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147\u201356.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1624_CR2","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863\u20139.","journal-title":"Blood"},{"issue":"6","key":"1624_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","volume":"27","author":"F Huguet","year":"2009","unstructured":"Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. JCO. 2009;27(6):911\u20138.","journal-title":"JCO"},{"issue":"8","key":"1624_CR4","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3324\/haematol.2020.251686","volume":"106","author":"MB Geyer","year":"2021","unstructured":"Geyer MB, Ritchie EK, Rao AV, et al. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021;106(8):2086\u201394.","journal-title":"Haematologica"},{"issue":"2","key":"1624_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","volume":"34","author":"P Quist-Paulsen","year":"2020","unstructured":"Quist-Paulsen P, Toft N, Heyman M, et al. T-cell acute lymphoblastic leukemia in patients 1\u201345 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020;34(2):347\u201357.","journal-title":"Leukemia"},{"issue":"3","key":"1624_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2014.229","volume":"29","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526\u201334.","journal-title":"Leukemia"},{"issue":"3","key":"1624_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.3088","volume":"41","author":"HY Cao","year":"2023","unstructured":"Cao HY, Li L, Xue SL, Dai HP. Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2023;41(3):301\u20139.","journal-title":"Hematol Oncol"},{"issue":"7380","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157\u201363.","journal-title":"Nature"},{"key":"1624_CR9","doi-asserted-by":"crossref","unstructured":"Ou J, Deng S, Ding C, et al Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia. Ann Hematol. Published online March 7, 2024.","DOI":"10.1007\/s00277-024-05681-4"},{"issue":"3","key":"1624_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11684-021-0877-y","volume":"16","author":"M Xi","year":"2022","unstructured":"Xi M, Guo S, Bayin C, et al. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia. Front Med. 2022;16(3):442\u201358.","journal-title":"Front Med"},{"issue":"2","key":"1624_CR11","first-page":"936","volume":"21","author":"Z Chi","year":"2020","unstructured":"Chi Z, Gao H, Liu H, et al. Chidamide induces necroptosis via regulation of c-FLIPL expression in Jurkat and HUT-78 cells. Mol Med Rep. 2020;21(2):936\u201344.","journal-title":"Mol Med Rep"},{"issue":"3","key":"1624_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","volume":"111","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060\u20136.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01624-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01624-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:06:48Z","timestamp":1730167608000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01624-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01624-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with the Declaration of Helsinki and the China Good Clinical Practice Guidelines, and was approved by the Medical Ethics Committee of Nanfang Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients or their guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}